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Abstract
           
           Non ischemic dilated cardiomyopathy (NIDCM) is a disorder of myocardium. It has 
varying etiologies.  Albeit the varying etiologies of this heart muscle disorder, it presents with 
symptoms of heart failure, and rarely as sudden cardiac death (SCD). Manifestations of this 
disorder are in many ways similar to its counterpart, ischemic dilated cardiomyopathy (IDCM). 
A proportion of patients with NIDCM carries a grave prognosis and is prone to sudden cardiac 
death from sustained ventricular arrhythmias. Identification of this subgroup of patients who 
carry the risk of sudden cardiac death despite adequate medical management is a challenge .Yet 
another method is a blanket treatment of patients with this disorder with anti arrhythmic 
medications or anti tachyarrhythmia devices like implantable cardioverter defibrillators (ICD). 
However this modality of treatment could be a costly exercise even for affluent economies. In 
this review we try to analyze the existing data of risk stratification of NIDCM and its clinical 
implications in practice.
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           Non-ischemic dilated cardiomyopathy (NIDCM) is a primary disease of the myocardium, 
characterized by dilatation of all four chambers of the heart, but primarily the left ventricle, with 
associated systolic dysfunction.  The incidence of dilated cardiomyopathy is 5 – 8 / 100,000 / 
year1,2.  In an international heart failure study it was found that 18% of symptomatic patients 
with ejection fraction less than 30% were diagnosed with NIDCM3.  The age-adjusted mortality 
in patients with NIDCM ranges from 0.10 per 10,000 person-years among men aged 35-39 up to 
1.16 per 10,000 person-years among men aged 55-572.  Currently, mortality in NIDCM is 12-
13% at 3 years4. Independent risk factors for death include smoking, diabetes mellitus, and high 
diastolic blood pressure2.  Patients with NIDCM suffer from heart failure mortality and sudden 
cardiac death in near equal numbers5.   Sudden cardiac death (SCD) may well be the first 
manifestation of NIDCM, and idiopathic NIDCM is responsible for 10% of all sudden cardiac 
deaths in adults6.  Survivors of SCD with NIDCM often have recurrent ventricular fibrillation as 
their clinical arrhythmia7.  
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            The majority of SCDs occur among patients that are classically defined as low risk, 
including those with NYHA functional class II or I.  In the MERIT-HF trial (NYHA heart 
failure class II-IV, EF < 40%), the most common cause of mortality in patients with NYHA 
functional classes II and III was sudden cardiac death8. The incidence of SCD in NYHA class 
IV heart failure is also high but the competing risk of pump failure makes it the second cause of 
death in this very sick category of patients.
            With the advent of the implantable cardioverter defibrillator (ICD) and their near-perfect 
termination of lethal arrhythmias, a determination needs to be made of which patients would 
benefit most from ICD insertion.  In order to balance the potential risks of device implantation 
and the associated cost, many investigators have sought to establish risk factors to select patients 
with NIDCM who would benefit most from ICD implantation.
Secondary Prevention Trials
               Patients with symptomatic NIDCM and documented ventricular tachycardia or 
ventricular fibrillation (VT/VF) have a mortality rate of up to 22% in the first two years after 
diagnosis.  This is comparable to a similar group of patients in the AVID registry with CAD9.  It 
has been clearly established that patients with symptomatic sustained ventricular tachycardia 
and underlying structural heart disease benefit from ICD implantation irrespective of the 
etiology of their heart disease10-21. Data from the AVID registry reveal a similar mortality rate in 
patient’s surviving symptomatic VT or VF regardless of the underlying nature of cardiac 
disease. The AVID trial, on the other hand, randomized patients resuscitated from ventricular 
arrhythmias to either ICD therapy or treatment with class III antiarrhythmic agents (primarily 
amiodarone)22.   Patients were randomized (n=1016) and 3117 patients were followed in the 
AVID registry.  The registry comprised 73% of the patients with CAD, while the remaining 
27% were diagnosed as NIDCM.  54% of NIDCM patients received ICDs, while 48% of CAD 
patients received ICDs. Analysis of the registry revealed that the overall 2-year survival of 
patients with NIDCM was 78.2%, which was similar to those with CAD.
Primary Prevention
               Primary prevention of sudden cardiac death is an important goal in the NIDCM 
population. Two trials using amiodarone in a randomized fashion against placebo have been 
performed in the NIDCM population. The GESICA trial randomized 516 patients with 
predominantly non-ischemic cardiomyopathies and ejection fraction <35% on optimal medical 
therapy to amiodarone or placebo23.  The trial demonstrated a substantial reduction in all cause 
mortality in patients treated with amiodarone (33.5% vs. 41.4% RR reduction 28%, 95% CI 4-
45%)   independent   of   the   presence   of   ventricular   arrhythmias.   Although   the   trial   was 
randomized, it was criticized for its non-blinded enrollment. Also many patients enrolled in this 
trial had cardiomyopathy from Chaga’s disease, which is a very different group of patients 
compared to NIDCM patients in the US or other parts of the world. 
            Similarly, CHF-STAT evaluated the use of amiodarone in a predominantly though not 
exclusively ischemic cardiomyopathy population with > 10 PVCs /hr.  Although the overall 
study showed no mortality benefit of amiodarone therapy, subgroup analysis of the 193 non-
ischemic participants demonstrated a trend towards reduction in all cause mortality24, with a P 
value of 0.07. One of the intriguing findings of this randomized, double blind trial was that 
arrhythmia suppression with amiodarone had no effect on survival. 
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               The Cardiomyopathy Trial (CAT) randomized 104 patients with NIDCM to ICD 
placement versus optimal medical management and followed them for greater than five years 
(5.5 ± 2.2 years).  ICD therapy had no significant benefit in comparison to medical therapy25.  
The trial may have been underpowered to detect a survival benefit, as the overall mortality did 
not reach the anticipated 30% in the control group.
            The Amiodarone Versus Implantable Cardioverter-Defibrillator in patients with non-
ischemic   dilated   cardiomyopathy   and   asymptomatic   nonsustained   ventricular   tachycardia 
(AMIOVIRT trial) evaluated empiric amiodarone therapy vs. prophylactic ICD implantation in 
103 patients with NIDCM, EF <35%, and asymptomatic NSVT.  The three-year survival rate 
was 89% in both arms of the study with no significant difference between amiodarone and ICD 
placement in either survival or quality of life endpoints (the trial was stopped at the first interim 
analysis).   Patients treated with amiodarone, however, showed a trend toward improved 
arrhythmia-free survival compared to the ICD arm.
            These two smaller trials, evaluating optimal medical therapy25 and amiodarone4 against 
prophylactic ICD placement, have suggested medical therapy to be as effective as ICD 
implantation in preventing all cause mortality in asymptomatic patients with NIDCM and non-
sustained ventricular tachycardia (NSVT). A more definitive assessment of the benefit of 
prophylactic ICD implantation in the NIDCM population was, however, performed in the 
Defibrillators in Non-ischemic  Cardiomyopathy  Treatment Evaluation  (DEFINITE) trial.  
DEFINITE compared the use of the ICD with standard oral medical therapy vs. medical therapy 
only of patients with NIDCM and NSVT.  Inclusion criteria for the trial included EF <35%, 
symptomatic heart failure, and documented ventricular ectopy (> 10 PVCs/hour) or NSVT on 
Holter monitor or telemetry within the last 6 months26. The trial randomized 458 patients. 
Arrhythmia mortality accounted for 33% of deaths.  At 2 years, mortality in the medical therapy 
arm was 13.8%, and was reduced to 8.1 % in the ICD arm (p=0.06).  The ICD group had a 74% 
reduction in arrhythmic deaths (p < 0.05). The trial’s primary endpoint (total mortality) failed to 
reach statistical significance; however, ICD’s were associated with a significantly lower rate of 
arrhythmic death, the study’s secondary endpoint. Subgroup analysis found that male patients, 
EF < 20%, QRS duration > 120 msec, and NYHA Class III received the greatest benefit from 
ICD implantation. NYHA class III was associated with a 67% risk reduction in all cause 
mortality (p=0.009). The DEFINITE trial has also been criticized for being underpowered.
            The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) is a recently published 
primary prevention trial.  It enrolled patients with EF < 36% and NYHA class II or III heart 
failure27  into three arms, medical therapy vs. medical therapy plus amiodarone vs. medical 
therapy plus ICD.  The endpoint of the study was all-cause mortality.  About half of the 2521 
patients enrolled had an underlying diagnosis of NIDCM.  The five-year all-cause mortality in 
the ICD group was 28.9%, compared to 34.1% in the amiodarone group and 35.8% in the 
placebo group.  This resulted in a reduction in five-year all-cause mortality by 23% with ICD 
use compared with the control group.  Amiodarone had no effect on survival.  The conclusion is 
that ICD implantation saves lives (but amiodarone doesn't) in patients with class 2 or 3 heart 
failure, irrespective of the etiology of heart failure. It is interesting to note that in patients with 
class III heart failure, irrespective of etiology, ICD implantation was associated with a 
significant survival advantage when compared to amiodarone but not when compared to 
placebo. As a result of this large randomized, double-blind trial incorporating a placebo arm, 
prophylactic ICD implantation in NIDCM patients with a LVEF <36% and NYHA functional 
class II or III seems justified and risk stratification in this group of patients may no longer be 
required. Other patient groups (eg. LVEF 36-40% or NYHA class I functional status) will, 
however, still need risk stratification.
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Risk Stratification
           Based on the primary prevention trials there seems to be still some controversy regarding 
improved survival with ICD therapy in patients with NIDCM. It is believed that benefit would 
be more readily achievable if a higher risk subgroup could be selected instead of allocating this 
expensive therapy to the broad population of patients with NIDCM. A number of diagnostic 
methods have been used to risk stratify patients with cardiomyopathy for elevated risk for 
sudden   death.   History   of   syncope28-30,   Electrocardiographic   monitoring31-36,   programmed 
electrical stimulation (PES)37-56, signal-averaged ECG (SAECG)56-58, heart rate variability48-59, 
QT dispersion46, and baroreceptor sensitivity testing60, heart rate turbulence63-65 have all been 
evaluated.
Syncope
            Syncope may be a harbinger of SCD.  Comparisons of patients without documented 
VT/VF but with a history of unexplained syncope and patients who have survived documented 
cardiac arrest reveal similar mortality29. In one particular trial 23 patients with NIDCM and 
syncope were compared to a similar group of 201 patients that did not have syncope28.  This 
trial was non-randomized, with more frequent use of amiodarone in the syncope group (p < 
0.04).  During the follow-up, there was no statistical difference in mortality between the two 
groups.   However, 83% of the mortality in the syncope group was due to sudden death, 
compared to 32% in the control group (P < 0.025).
               Knight et al. prospectively followed 14 patients who presented with unexplained 
syncope and who were diagnosed with NIDCM, and had negative electrophysiology study29 
along with a control group of 19 patients with NIDCM who sustained a cardiac arrest.  All 
patients in both arms of the study received an ICD.  During the 24 ± 13 months of follow-up, 
50% of patients with unexplained syncope received appropriate ICD shocks in comparison to 
42% of the patients who received an ICD for cardiac arrest (P=0.1).  Time to first appropriate 
ICD shock actually occurred earlier in the syncope patients as compared to those with cardiac 
arrest (32+7 vs. 72+12 months, p =0.01).  Due to the small number of patients in this study, the 
results were not statistically significant.  However, the trend suggests that syncope is a marker 
for arrhythmic death in patients with NIDCM.
            Fonarow et al. evaluated 147 patients with NIDCM, syncope, and severely decreased left 
ventricular function30.  Twenty-five patients underwent ICD implantation and were compared to 
122 controls that were treated medically.  The 2-year survival was 84.9% in the ICD group 
compared to 66.9% in the medically treated group (P=0.04).   While this trial was non-
randomized, the ICD group had significantly improved 2-year survival although they had more 
frequent ventricular arrhythmias during monitoring (56% vs. 15% P=0.0001).
            These studies suggest that unexplained syncope in patients with NIDCM is a grave 
prognostic indicator with a significant proportion benefiting from ICD implantation; however 
that is not to imply that absence of syncope confers any protection from sudden death.
Electrocardiographic Monitoring
               The prognostic influence of electrocardiographic monitoring for the presence of 
ventricular arrhythmias has been debated for nearly two decades. The incidence of NSVT in 
patients with NIDCM varies from 33 to 79%31,32.  Survival in such patients at one year is 92%, 
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and decreases to 88% at two years4.  Huang et al. followed 35 patients with recently diagnosed 
NIDCM that had ambulatory electrocardiographic monitoring to evaluate for ventricular 
arrhythmias33. At baseline, 83% had frequent PVCs, 93% had complex PVCs and 60% of 
patients had NSVT.  During follow-up of 34 ± 17 months there were 4 deaths, two of which 
were sudden. Of the two patients who suffered sudden death during follow-up, one had no 
evidence of ventricular arrhythmias at baseline.  While this study showed a high incidence of 
NSVT in the NIDCM population, it was not powered to show any correlation between NSVT 
and sudden death.
            Olshausen et al. followed a group of 73 patients with NIDCM for a minimum of 3 
years34.  All patients received ambulatory holter monitoring at baseline.  During follow-up, 38% 
of patients expired. The deaths were evenly divided between those that died of pump failure and 
those that died due to sudden death.  NSVT was a risk factor for death due to pump failure, but 
was not for sudden death. On the other hand, Becker et al. followed 256 patients with 
NIDCM35.  Of those, 99 patients had documented asymptomatic NSVT, while 157 controls with 
NIDCM were free of documented ventricular arrhythmias.   During the 22 ± 14 months of 
follow-up, both overall mortality and mortality due to sudden death were higher in patients with 
NSVT than those without arrhythmias (34.2 vs. 9.8%, P=0.0001 and 15.8 vs. 3.7%, P=0.0037).
            Grimm et al. recently assessed a cohort of 343 patients with NIDCM using multiple 
diagnostic tests to assess risk for sudden death36.  During the 52 ± 21 months of follow-up, 13% 
of patients had a major arrhythmic event (sustained VT, VF, or sudden death).  Ejection fraction 
was found to be the only significant predictor of a major arrhythmic event, with a relative risk 
reduction of 2.3 for every 10% increase in ejection fraction (95% CI, 1.5 to 3.3, p=0.0001).  The 
finding of NSVT on holter monitoring was associated with a trend towards an increased risk of 
major arrhythmic events (RR 1.7, 95% CI 0.9 to 3.3, p=0.11).
            The prognostic value of NSVT or frequent ventricular arrhythmias remains unclear. The 
weight of evidence suggest that it is predominantly a marker of risk for all cause mortality but is 
not   very   effective   in   selecting   a   high   risk   group   for   sudden   arrhythmic   death.  
Electrophysiologic Testing 
            Programmed electrical stimulation (PES) has been evaluated in NIDCM.  The studies 
performed were often non-randomized and had small numbers of patients (Table 1). In addition, 
the  variability  of   stimulation  protocols  makes  assessment  of  predictive  values  difficult. 
Sustained ventricular arrhythmias (monomorphic and polymorphic VT, or VF) may be induced 
in up to 38% of patients with NIDCM undergoing PES, but this may have limited clinical 
significance37.
            The reproducibility of programmed stimulation is greater in patient’s who presented with 
clinical   VT   as   opposed   to  those  with   ventricular   fibrillation.   Milner   et   al.   performed 
programmed stimulation in 19 patients with NIDCM and symptomatic ventricular arrhythmias; 
10 had survived an out-of-hospital cardiac arrest, 8 had monomorphic VT (MMVT), and 1 had 
NSVT38.  The mean ejection fraction in this group was 26 ± 9%.  13 (68%) of these patients had 
their clinical arrhythmia reproduced in the EP lab.  The most frequently reproduced rhythm was 
MMVT (92%), while VF was reproducible in only one patient (8%).  Monomorphic VT induced 
with   programmed   stimulation   does   appear   to   predict   future   occurrence   of   spontaneous 
monomorphic VT of a similar rate and configuration38,39.  
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            Nevertheless, the diagnostic yield of PES in the NIDCM population has been poor. 
Stamato et al. performed PES in 15 patients with NIDCM and heart failure40.  The mean EF in 
this group was 17%, and they all had NSVT on cardiac monitoring.  PES in this group failed to 
produce a sustained ventricular arrhythmia in any patients.  Similarly, Das et al. performed PES 
in 24 patients with NIDCM and a mean ejection fraction of 25 ± 12%.   While ventricular 
arrhythmias were induced in 42% of patients, MMVT was seen in only 8% of the group. 
            Furthermore the specificity of induced arrhythmias has been called into question. The 
most common finding with PES in patients with NIDCM is inducible polymorphic VT or 
VF37,41,39.   Meinertz et al. evaluated 42 patients with NIDCM and performed PES in all 
patients41.  86% of the study group had polymorphic ventricular arrhythmias, with three or more 
beats of PMVT induced in 26% of the study group.  During the 16 ± 7 months of follow-up, 5% 
of patients died of sudden death.   None of the patients who suffered sudden death had an 
induced arrhythmia during PES.  This suggests that the positive predictive value of induced 
polymorphic ventricular arrhythmias is low in the NIDCM population.
               The use of PES for risk stratification in the NIDCM population has not provided 
satisfying results. Aside from the rare occasion of inducible MMVT, PES may frequently result 
in the induction of non-specific arrhythmias.  The negative predictive value of a normal study is 
poor as well.
Signal Averaged ECG
            Several groups have evaluated the performance of the signal averaged ECG (SAECG) to 
stratify risk for SCD.   Many of these studies did not differentiate between CAD and non-
ischemic causes of cardiomyopathy, and were not powered for mortality in the NIDCM 
population. Galinier et al. prospectively followed 151 patients with CHF, 48% of which were 
diagnosed with NIDCM42.   At baseline, late potentials were detected in 32.5% of the total 
patient population.  34% of the NIDCM patients were found to have late potentials (similar to 
the incidence of late potentials in patient’s with CAD).  Late potentials were not found to be 
predictive of overall mortality or sudden cardiac death but did improve risk stratification for 
sustained ventricular tachycardia. 
            In a group of NIDCM patients, Fauchier et al. performed SAECG in 131 patients with 
mean ejection fraction of 33 ± 12% and followed them for 54 ± 41 months43.  Late potentials 
were present in 27% of the patients.   During follow-up, 15% of the patients had major 
arrhythmic events.  Patients with late potentials were found to be at increased risk of all-cause 
cardiac death (RR 3.3, 95% CI 1.5 to 7.5, P = 0.004) and of arrhythmic events (RR 7.2, 95% CI 
2.6 to 19.4, P = 0.0001), but not sudden death.
            The studies of SAECG in the NIDCM population are complicated by the inclusion of 
individuals with bundle branch blocks(BBB), which compromises the utility of the SAECG as 
an adequate method for risk stratification in this population.   Mancini et al. evaluated 114 
patients with NIDCM with SAECG44.   In the first year of follow-up, survival was 95% in 
patients with a normal SAECG, 88% in patients with a BBB, and only 39% in patients with an 
abnormal SAECG (P < 0.001).  During follow-up, of the 20 patients with an abnormal SAECG, 
5 (20%) suffered a sudden death, and three others either died from progressive heart failure or 
required urgent cardiac transplantation.   This suggests that an abnormal SAECG confers an 
increased risk for an arrhythmic episode within a relatively short follow-up period.  This study 
was flawed, however, because of the non-uniform implantation of ICDs in the study group, with 
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patients   with   BBB   having   significantly   more   ICDs   placed   at   baseline   (P   <   0.05).
    
               An abnormal result on SAECG may be a marker of increased risk of sustained 
ventricular tachycardia or death43,44.  As such, the SAECG appears to have an excellent negative 
predictive value, with the caveat that the presence of bundle branch block may significantly 
decrease  the  specificity  of   SAECG45.   However,   the  poor  positive  predictive  value  for 
arrhythmic events and decreased specificity in the significant number of patients with bundle 
branch block lessens the value of this test.
QT Dispersion
            QT dispersion (QTd) has been studied in the risk stratification of SCD in patients with 
NIDCM.   Few studies have been done, and the results have been unfavorable. Grim et al. 
performed QT dispersion and related measures in 107 patients with NIDCM and 100 controls 
without structural heart disease and followed them for 13 ± 7 months46.  During follow-up, 11% 
of patients with NIDCM had an arrhythmic event, defined as sustained VT, VF, or sudden 
death.  QT dispersion was noted to be increased in patients with arrhythmic events compared to 
patients without an arrhythmia during follow-up (76 ± 17 vs 60 ± 26 ms, P=0.03).  On the other 
hand, corrected QT dispersion (QTc) and adjusted QTc were not statistically different between 
those with and those without arrhythmias during follow-up (80 ± 21 vs 75 ± 35 ms, and 27 ± 6 
vs 24 ± 10 ms). This modality is limited due to the overlap between groups with positive and 
negative results. The Marburg Cardiomyopathy Study36, confirmed that QT dispersion does not 
significantly risk stratify patients for sudden death.
HR Variability
            Measures of autonomic function have been evaluated to assess risk for SCD.  Heart rate 
variability is an indirect measure of autonomic tone.  Previous studies have shown that heart rate 
variability (HRV) is predictive of arrhythmic events following myocardial infarction (Table 2).  
The ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) study showed that 
both decreased HRV and baro-receptor sensitivity, another measure of autonomic tone, are 
associated with worse outcomes in patients after myocardial infarction47.
            HRV was evaluated in 70 patients with NIDCM and prophylactic ICD implantation.  
Patients with sustained ventricular arrhythmias as recorded by their defibrillator had similar 
HRV to those who had no arrhythmic events48.  Other trials have shown that in patients with 
NIDCM, HRV was predictive of cardiac death but not ventricular arrhythmias49,50.  Patients 
with NIDCM have decreased heart rate variability.  However, this decrease is associated with 
systolic   ventricular   function,   and   does   not   correlate   with   increased   risk   of   ventricular 
arrhythmias49.  The weight of the evidence suggests that due to the poor positive predictive 
value of HRV, this test has no role in the risk stratification for sudden death of patients with 
NIDCM48-50.
Baroreceptor Sensitivity Testing
            Studies of baroreceptor sensitivity (BRS) in the NIDCM population have not focused on 
risk stratification for sudden death until recently36. Menz et al. compared BRS against heart rate 
variability in a series of 179 patients including those with CAD (27%) and NIDCM (73%)51.  
This trial was designed to determine if there were any differences in these two diagnostic tests 
in a baseline group of patients with decreased EF.   It was not designed for assessment of 
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prognostic value.  Baroreceptor sensitivity was comparable in patients with CAD and NIDCM 
(6.1 ± 3 vs 6.9 ± 5 ms/mmHg, P=NS).  
            Grimm, et at. Performed an exhaustive trial of risk stratification techniques in patients 
with NIDCM, including BRS36.  343 patients with NIDCM underwent BRS testing, with 26 
patients (10%) being excluded due to insufficient response to phenylephrine during BRS 
testing.  No correlation was noted between BRS results and sudden death during the 52 ± 21 
months of follow-up. The evidence to date suggests that BRS is not a reliable risk stratifier for 
sudden death in NIDCM, and may not have additional benefit over other markers of autonomic 
tone, such as heart rate variability. 
Microvolt T Wave Alternans
               Microvolt T Wave Alternans (TWA) is due to beat-to-beat alterations in cellular 
repolarization due to changes in action potential duration. Kitamura et al described an increased 
risk of SCD or sustained VT/VF in patients with a history of NIDCM with occurrence of 
microvolt level TWA at sufficiently low heart rate52.  Onset of TWA with heart rates below 
100/minute conferred increased risk of SCD or sustained VT/VF, with a predictive accuracy of 
78%52.  The onset HR of patients with TWA is independent of the more standard risk factors, 
including LV ejection fraction, gender, systolic or diastolic BP, or NYHA functional class.  This 
makes it attractive in risk stratifying patients with NIDCM.   Unfortunately TWA can be 
indeterminate in as many as 20% of patients with NIDCM52, 53. Combining it with the presence 
of late potentials on SAECG54 may increase the sensitivity of TWA.
            A recent study by Hohnloser et al looked at 137 patients with NIDCM referred to a 
single center for diagnosis or management of heart failure or evaluation of symptomatic 
arrhythmias55.  The follow-up was 14 ± 6 months, with endpoints defined as sudden death and 
hemodynamically unstable VT or VF.  37 patients in the study had prior ICD implantation.  
TWA at heart rates <110/minutes had a positive predictive value of 22% ± 5% and a negative 
predicative value of 94% ± 4%.   The strong negative predictive value of sustained TWA 
demonstrated in this study at heart rates <110 bpm suggests a role of TWA testing in risk 
stratification of patients with NIDCM (Table 3).  Further studies to look at larger, more diverse 
populations, long-term follow-up, and the benefits of serial TWA measurements will clarify the 
role of this test in risk stratification of patients with NIDCM.
Heart Rate Turbulence
               Heart rate turbulence is an emerging risk profiling method in patients with heart 
disease63-65. It is a method which is based on the electrical property of the heart after a 
ventricular ectopic beat and can be measured from a 12 lead electrocardiogram or holter 
monitoring. Immediately post ventricular ectopic beat the native ventricular response accelerates 
(due to baroreflex activity because of decreased cardiac output) and followed by a slow 
deceleration back to normalcy. Measurement of these variables when studied along with other 
risk factors has shown superior risk prediction for sudden cardiac death. This method however 
will need to be validated with prospective clinical studies.
Conclusion
              As the treatment of heart failure from Non-ischemic dilated cardiomyopathy   CHF 
becomes more refined, it is expected that death from pump failure will be delayed, and risk 
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stratification of these patients for arrhythmic death will become more important.  Proper risk 
stratification based on symptoms, signs, and judicious use of noninvasive and invasive testing is 
important   to   determine   the   subgroup   of   patients   that   would   benefit   most   from   ICD 
implantation. 
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            The most effective treatment and prophylaxis for SCD is implantation of an ICD.  Due 
to the considerable cost considerations of these devices it would probably be uneconomical to 
place these devices in all patients with NIDCM.  While it may be expected that the price of 
these devices individually will decrease over time, due to the increasing number of expected 
implantations the overall cost to the healthcare system is not likely to diminish. More over 
majority of the health systems cannot afford these expensive devices on a “blanket” basis. When 
compared to similar patients with ischemic cardiomyopathy, it appears that the non-ischemic 
dilated cardiomyopathy patient has a less certain clinical course in terms of sudden cardiac 
death.   Most of the current trials of risk stratification for patients with NIDCM, with the 
exception of the SCD-HeFT trial, are underpowered and non-randomized.   Clearly further 
studies that define the precise role of various risk stratification modalities need to be performed. 
Current indications for ICD implantation miss a fairly large number of patients at risk for 
sudden death. Appropriate primary prevention and secondary prevention of cardiac arrest in this 
population will require effective risk stratification to allow delivery of life saving therapy in an 
economically reasonable fashion.
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